Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · EBS · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
8
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Emergent BioSolutions Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
EBS insider buying and selling by quarter
EBS insider selling · EBS insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · EBS ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
EBS executive sell shares · EBS board member insider trading · EBS insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Apr 30, 2026 | Dayal Sujata Tyagi Director | Award | 25,344 | — | Form 4 |
| May 1, 2026 | Dayal Sujata Tyagi Director | Sale | 12,781 | $107K | Form 4 |
| May 1, 2026 | Dayal Sujata Tyagi Director | Sale | 980 | $9K | Form 4 |
| Apr 30, 2026 | DeGolyer Donald W Director | Award | 25,344 | — | Form 4 |
| May 1, 2026 | DeGolyer Donald W Director | Sale | 14,527 | $121K | Form 4 |
| May 1, 2026 | DeGolyer Donald W Director | Sale | 954 | $9K | Form 4 |
| Apr 30, 2026 | Katkin Keith Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Katkin Keith Director | Sale | 15,481 | $128K | Form 4 |
| Apr 30, 2026 | White Marvin L Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | FOWLER JOHN D JR Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Richard Ronald Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Zoon Kathryn C Director | Award | 25,344 | — | Form 4 |
| May 1, 2026 | Zoon Kathryn C Director | Sale | 16,145 | $135K | Form 4 |
| May 1, 2026 | Zoon Kathryn C Director | Sale | 1,057 | $9K | Form 4 |
| Apr 30, 2026 | Fowler Neal Franklin Director | Award | 25,344 | — | Form 4 |
| Apr 30, 2026 | Harsanyi Zsolt Chairman · Director | Award | 25,344 | — | Form 4 |
| Apr 29, 2026 | Williams Paul Anthony SVP, Products Business | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | Lowry Simon C SVP, R&D, CMO | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | Glessner Coleen EVP, Quality & Ethics, and CPL | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | LINDAHL RICHARD S EVP, Chief Financial Officer | Award | 162,680 | — | Form 4 |
| Apr 29, 2026 | Perl Jessica SVP, General Counsel, Corp Sec | Award | 104,282 | — | Form 4 |
| Apr 29, 2026 | Hartzel William SVP, Bioservices | Award | 100,111 | — | Form 4 |
| Apr 29, 2026 | PAPA JOSEPH C President and CEO · Director | Award | 187,708 | — | Form 4 |
| Apr 1, 2026 | Williams Paul Anthony SVP, Products Business | Sale | 4,000 | $34K | Form 4 |
| Mar 5, 2026 | PAPA JOSEPH C President and CEO · Director | Other | 37,055 | $313K | Form 4 |
Williams Paul Anthony
SVP, Products Business
Date
Apr 29
Shares
100,111
Price
—
Value
—
Glessner Coleen
EVP, Quality & Ethics, and CPL
Date
Apr 29
Shares
100,111
Price
—
Value
—
LINDAHL RICHARD S
EVP, Chief Financial Officer
Date
Apr 29
Shares
162,680
Price
—
Value
—
Perl Jessica
SVP, General Counsel, Corp Sec
Date
Apr 29
Shares
104,282
Price
—
Value
—
PAPA JOSEPH C
President and CEO · Director
Date
Apr 29
Shares
187,708
Price
—
Value
—
Williams Paul Anthony
SVP, Products Business
Date
Apr 1
Shares
4,000
Price
$8.44
Value
$34K
PAPA JOSEPH C
President and CEO · Director
Date
Mar 5
Shares
37,055
Price
$8.44
Value
$313K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About EBS insider trading
EBS insider trades
Emergent BioSolutions Inc. (EBS) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including LINDAHL RICHARD S (EVP, Chief Financial Officer), Hartzel William (SVP, Bioservices), DeGolyer Donald W (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. EBS insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Emergent BioSolutions Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
EBS insider trading · 5 questionsThe insiders of Emergent BioSolutions Inc. (EBS) include executives and directors such as LINDAHL RICHARD S (EVP, Chief Financial Officer), Hartzel William (SVP, Bioservices), DeGolyer Donald W (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026